Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kallikrein-related peptidase 14 (KLK14) is a serine protease involved in tissue remodeling, skin homeostasis, and cancer progression. It is produced as an inactive zymogen and activated by proteolytic cleavage. KLK14 participates in skin desquamation and is implicated in inflammatory skin diseases. It is overexpressed in prostate cancer and is associated with aggressive features and metastasis. It modulates signaling pathways relevant to cancer progression, including the MAP kinase and Interleukin-1 receptor pathways. KLK14 regulates genes involved in tumor biology and cellular migration/invasion. It is considered a potential therapeutic target and biomarker for cancer aggressiveness and treatment response.
Inhibition of serine protease activity of KLK14
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kallikrein-related Peptidase 14.